David Berz
Overview
Explore the profile of David Berz including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
33
Citations
669
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Heymach J, Opdam F, Barve M, Tu H, Wu Y, Berz D, et al.
J Clin Oncol
. 2025 Mar;
:JCO2401727.
PMID: 40030100
Purpose: Human epidermal growth factor receptor 2 (HER2) alterations occur in many solid cancers, including non-small cell lung cancer (NSCLC). Beamion LUNG-1 (ClinicalTrials.gov identifier: NCT04886804) is assessing the safety/efficacy of...
2.
Harrington K, Kitano S, Gambardella V, Parkes E, Moreno I, Alonso G, et al.
Future Oncol
. 2025 Jan;
21(2):195-200.
PMID: 39817655
BI 1703880, a novel STimulator of INterferon Genes (STING) agonist, has demonstrated preclinical antitumor activity. As STING activation can upregulate programmed death ligand 1 and human leukocyte antigen in tumor...
3.
Subbiah V, Chawla S, Conley A, Wilky B, Tolcher A, Lakhani N, et al.
Clin Cancer Res
. 2023 Jun;
29(16):2988-3003.
PMID: 37265425
Purpose: Patients with unresectable/metastatic chondrosarcoma have poor prognoses; conventional chondrosarcoma is associated with a median progression-free survival (PFS) of <4 months after first-line chemotherapy. No standard targeted therapies are available....
4.
He K, Berz D, Gadgeel S, Iams W, Bruno D, Blakely C, et al.
J Thorac Oncol
. 2023 Feb;
18(7):907-921.
PMID: 36842467
Introduction: Sitravatinib, a receptor tyrosine kinase inhibitor targeting TYRO3, AXL, MERTK receptors, and vascular epithelial growth factor receptor 2, can shift the tumor microenvironment toward an immunostimulatory state. Combining sitravatinib...
5.
Spigel D, Jotte R, Nemunaitis J, Shum M, Schneider J, Goldschmidt J, et al.
J Thorac Oncol
. 2020 Nov;
16(2):327-333.
PMID: 33166722
Introduction: Checkpoint inhibitors (CPIs) have been approved to treat metastatic NSCLC. Pegilodecakin + CPI suggested promising efficacy in phase 1 IVY, providing rationale for randomized phase 2 trials CYPRESS 1...
6.
Yang J, Camidge D, Yang C, Zhou J, Guo R, Chiu C, et al.
J Thorac Oncol
. 2020 Sep;
15(12):1907-1918.
PMID: 32916310
Introduction: Almonertinib (HS-10296) is a novel, third-generation EGFR tyrosine kinase inhibitor (EGFR TKI) that targets both EGFR-sensitizing and T790M resistance mutations. This first-in-human trial aimed to evaluate the safety, efficacy,...
7.
Bose C, Yadav S, Singhal S, Singhal J, Hindle A, Lee J, et al.
Cancers (Basel)
. 2020 Jun;
12(6).
PMID: 32498332
RLIP76 (RAL-binding protein-1, Rlip) is a stress-protective mercapturic-acid-pathway transporter protein that also plays a key role in regulating clathrin-dependent endocytosis as a Ral effector. Targeted inhibition or depletion of Rlip...
8.
Espinoza-Mercado F, Borgella J, Berz D, Alban R, Sarkissian A, Imai H, et al.
Ann Thorac Surg
. 2019 Apr;
108(3):889-896.
PMID: 31004585
Background: Current guidelines support cancer-directed surgery, chemotherapy, or active surveillance for clinical stages 1 to 3 of epithelial malignant pleural mesothelioma (MPM). Definitive chemotherapy is recommended for sarcomatoid/biphasic histologies. Our...
9.
Awasthi S, Singhal S, Singhal J, Nagaprashantha L, Li H, Yuan Y, et al.
Oncotarget
. 2018 Dec;
9(90):36202-36219.
PMID: 30546837
In previous studies, we found that 2'-hydroxyflavonone (2HF), a citrus flavonoid, inhibits the growth of renal cell carcinoma in a VHL-dependent manner. This was associated with the inhibition of glutathione...
10.
Tchekmedyian N, Mudad R, Blanco F, Raymond V, Garst J, Erlander M, et al.
Lung Cancer
. 2017 Jun;
108:22-28.
PMID: 28625639
Targetable, somatic EGFR mutations are highly prevalent in patients with non-small cell lung cancer (NSCLC), making them eligible for tyrosine kinase inhibitor (TKI) therapy. Circulating tumor DNA (ctDNA), isolated from...